Clinical Study
The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial
Table 2
Number of patients with progression by disease course.
| | | Fluoxetine | Placebo |
| | All () | 20 | 22 | | Progression | 7 (35%) | 7 (32%) | | Time to progression (months; mean, sd) | 7.7 (5.2) | 10.7 (6.4) | | EDSS progression | 5 (25%) | 7 (32%) | | 9HPT progression | 1 (5%) | 3 (14%) | | AI progression | 2 (10%) | 1 (4.5%) |
| | SPMS () | 14 | 15 | | Progression SPMS | 5 (36%) | 5 (33%) | | Time to progression (months; mean, sd) | 9.0 (5.6) | 12.0 (6.7) | | EDSS progression SPMS | 3 (21%) | 5 (33%) | | 9HPT progression SPMS | 1 (7%) | 2 (13%) | | AI progression SPMS | 1 (7%) | 1 (6.7%) |
| | PPMS () | 6 | 7 | | Progression PPMS | 2 (33%) | 2 (29%) | | Time to progression (months; mean, sd) | 4.5 (2.1) | 7.5 (6.4) | | EDSS progression PPMS | 2 (33%) | 2 (29%) | | 9HPT progression PPMS | 0 (0%) | 1 (14%) | | AI progression PPMS | 1 (17%) | 0 (0%) |
|
|
EDSS: Expanded Disability Status Scale; 9HPT: 9-hole peg test; AI: ambulation index.
|
